乳腺癌病人高危型人乳头状瘤病毒感染临床研究

Clinical research of high risk human papillomavirus infection in breast cancer

目的探讨高危型人乳头状瘤病毒感染与乳腺癌临床及病理特点方面的相关性。方法2008年5月至11月山东大学齐鲁医院乳腺外科采集经病理证实的85例乳腺癌及20例乳腺良性病变的活组织标本,采用二代杂交捕获试验(HC2)进行HPVDNA检测,同时检测雌激素受体(ER)、孕激素受体(PR)及Her-2基因表达情况。结果85例乳腺癌样本中,高危型人乳头状瘤病毒阳性率为30.6%(26/85);与良性病变组(阳性率为0)差异有统计学意义(P=0.01);40岁以下乳腺癌病人HR-HPV阳性率为69.2%(9/13),明显高于40岁以上病人(23.6%,17/72,P=0.027);HR-HPV阳性率在不同临床及病理学特点的乳腺癌中差异没有统计学意义。结论乳腺癌组织中确实存在HR-HPV感染,HR-HPV在乳腺癌的发病过程中可能起着重要作用。

Objective To examine the infection of high risk human papillomavirus （HR-HPV） in breast cancer and determine the association between HR-HPV infection and clinical and pathological characters of breast cancer. Methods The exfoliated cells were collected from 85 malignant and 20 benign breast tumors. 13 subtypes HR-HPV DNA were detected by hybrid capture 2（HC2） system. ER, PR and Her-2 of all the breast tumors were also detected. Results HR-HPV DNA was positive in 26 out of 85 breast cancer tumors and none of 20 benign breast diseases（P = 0.01）. 69.2% breast cancer tumors was HR-HPV DNA positive before age 40 while in the patients after age 40 the HR-HPV DNA positive rate was 23.6% （P =0.027）. There was no difference between the breast tumors with different clinical and pathology characters. Conclusions HR-HPV DNA infection exists in breast cancer tissues and it probably runs a roll in the onset of breast cancer.